Brain

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S.…

1 year ago

Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations

CE Marking for the company’s portable MRI system with AI-powered imaging software demonstrates that the system complies with safety and…

1 year ago

Neuronetics Sponsors the 5th International Brain Stimulation Conference

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced TherapyMALVERN, Pa.,…

1 year ago

Ocean Biomedical to Ring The Nasdaq Stock Market Opening Bell

Ocean Biomedical commenced trading on Nasdaq under ticker symbol "OCEA" on February 15 Providence, RI and New York, NY, Feb.…

1 year ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Prestigious award presented by Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping FoundationPALO ALTO, Calif. and…

1 year ago

Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY

OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results…

1 year ago

Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy

NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment,…

1 year ago

DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI

CERVAI™ to be available in May 2023TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”)…

1 year ago

KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy

KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy Cord blood-derived T-Cell Receptor…

1 year ago

Acasti Pharma Reports Third Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc.…

1 year ago